BibTex RIS Kaynak Göster

-

Yıl 2015, Cilt: 7 Sayı: 1, 57 - 60, 01.04.2015

Temel T

https://doi.org/10.18521/ktd.95339

Öz

Objective: Primary liver cancer is one of the most common and lethal type of tumors in the world. Hepatocellular forms compose about 80% of all primary liver tumors. Our aim is to evaluate the patients with hepatocellular carcinoma admitted to our clinic retrospectively. Methods: First we identified viral hepatitis serology and whether antiviral treatment was administered before the diagnosis and the period until the development of hepatocellular carcinoma for each case with hepatocellular carcinoma. Child-Pugh stage in cirrhotic cases, the stage of viral hepatitis in non-cirrhotic cases, and the treatment method suggested for hepatocellular carcinoma and the average life expectancy (for the patients whose life expectancy is known) were evaluated. Alphafeto protein levels and computerized tomography, ultrasound, magnetic resonance imaging findings were evaluated retrospectively. Correlation between alpha-feto protein levels and tumor numbers were evaluated statistically. Results: Total of 69 patients were evaluated. The median age at presentation was 62.8 (ranging from 25 to 80) years. Median (overall survival) OS was 7.0 (ranging from 0 to 145) months in all patients. 18 patients (41.9%) were Child-Pugh Class A, 12 (27.9%) patients were Child-Pugh Class B and 13 (30.2%) patients were ChildPugh Class C. It was found that patients with severely high alpha-feto protein levels (>200 ng/ml), have 4 fold risk of multiple liver masses (OR: 4.05, 95% CI: 1.2213.42). For the characterization of a liver mass as hepatocellular carcinoma, the diagnostic effectiveness of computerized tomography was 54.3%, and that of magnetic resonance imaging was 55.8%. Conclusion: As a result the patients with hepatocellular carcinoma can be diagnosed with combination of laboratory findings and imaging techniques. Alpha-feto protein levels are important for follow up of such patients and identifying the multiple mass presences

Anahtar Kelimeler

Hepatocellular Carcinoma Alpha-Feto Protein Imaging Retrospective

Kaynakça

  • Dogan E, Yalcin S, Koca D, Olmez A. Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev 2012;13(6):2985-90.
  • Bosch FX, Ribes J. Epidemiology of primary liver cancer. Global epidemiology. In: Tabor E. editors. Vıruses and Liver Cancer. Netherlands: Elsevier Science B.V; 2002:1-16.
  • Sewart BW, Kleihues P. World Cancer Report. Lyon: IARC Pres 2003:11–9.
  • Uzunalimoglu O, Yurdaydin C, Cetinkaya H, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001;46:1022–8.
  • Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325(10):675-80.
  • Abdo AA, Karim HA, Al Fuhaid T, et al. Diagnosis and management of hepatocellular carcinoma. The Saudi Journal of Gastroenterology 2007;13 (suppl):S1-24.
  • Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14(27): 4300-8.
  • Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75(3):347-54.
  • Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50.
  • Cottone M, Turri M, Caltagirone M, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994;21(6):1029- 34.
  • Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313(20):1256-62.
  • Fargion S, Fracanzani AL, Piperno A, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994 20(6):1426-31.
  • Polio J, Enriquez RE, Chow A, Wood WM, Atterbury CE. Hepatocellular carcinoma in Wilson's disease. Case report and review of the literature. J Clin Gastroenterol 1989;11(2):220-4.
  • Kew M. Hepatic tumors and cysts. In: Feldman M, Frıedman SL, Brandt LJ editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Philadelphia: Saunders, 2006:2007-33.
  • Pons F, Llovet JM. Approaching focal liver lesions. Rev Esp Enferm Dig 2004;96(8):567-73.
  • Reddy KR, Schiff E. Approach to a liver mass. Seminars in liver disease 1993; 13(4): 423-35.
  • Rubin RA, Mithchell DG. Evaluation of the solid hepatic mass. Med Clin North Am 1996;80(5): 907-28.
  • Ros PR, Davis GL. The incidental focal liver lesion: photon, proton, or needle? Hepatology 1998;27(5): 1183-90.
  • Pons F, Llovet JM. Approaching focal liver lesions. Rev Esp Enferm Dig 2004;96(8):567-77.
  • Song do S, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol 2012;18(3):258-67.
  • Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007;33(5):437-47.
  • Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19(1):61-7.
  • Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994, 20(1):65-71.
  • Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78(5):977-83.
  • Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009;16(7):453-463.
  • Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett 2009;286(1):5-8.
  • Gomaa AI, Khan SA, Leen ELS, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009;15(11): 1301-14.
  • Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett 2009;286(1):5-8.
  • Leong TY, Leong AS. Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB 2005;7(1):5- 15.
  • But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008;14(11):1652-6.

Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi

Yıl 2015, Cilt: 7 Sayı: 1, 57 - 60, 01.04.2015

Temel T

https://doi.org/10.18521/ktd.95339

Öz

Amaç: Primer karaciğer kanserleri, dünyada en sık ve en ölümcül tümörlerden birisidir. Hepatosellüler formları tüm primer karaciğer tümörlerinin yaklaşık %80’idir. Bu çalışmada amacımız kliniğimize başvuran hepatosellüler kanserli olguların retrospektif değerlendirmesini yapmaktır. Yöntem: Öncelikle hepatosellüler karsinomalı her birey, tanı koyma aşamasında ve hepatosellüler karsinoma gelişimi döneminde var olan viral hepatit serolojisi yönünden ve antiviral tedavi alıp almadıkları yönünden incelendi. Sirotik hastalarda Child-Pugh evresi, non-sirotik vakalarda viral hepatitin evresi ve yaşam beklentisi bilinen hastalarda ortalama yaşam beklentisi değerlendirildi. Alfa-feto protein, kompüterize tomografi, ultrason ve manyetik rezonans görüntüleme bulguları retrospektif olarak değerlendirildi. Alfa-feto Protein seviyeleri ve tümör sayıları arasında ki ilişki istatistiksel olarak araştırıldı. Bulgular: Toplam 69 hasta değerlendirildi. Başvurudaki ortalama yaş değerleri 62,8 (25-80 yaş) yıldı. Ortalama yaşam beklentisi tüm hastalar için 7,0 ay (0-145 ay) olarak hesaplandı. 18 hasta (%41,9) Child-Pugh sınıf A, 12 (%27,9) hasta ChildPugh sınıf B ve 13 hasta (%30,2) Child-Pugh sınıf C olarak değerlendirildi. Aşırı alfa-feto protein seviyesi (>200 ng/ml) olan hastalarda multipl karaciğer kitlesine rastlanma riski 4 kat (OR: 4,05, %95 CI: 1,22-13,42) daha yüksek bulundu. Karaciğer kitlesini hepatosellüler karsinom olarak tanımlamada ki etkilerine bakıldığında tanısal etkinlik kompüterize tomografide %54,3, manyetik rezonans görüntülemede ise %55,8 olarak bulundu. Sonuç: Sonuç olarak hepatosellüler karsinom tanısı laboratuvar ve görüntüleme teknikleri ile konur. Alfa-feto protein seviyeleri bu hastaların takibinde ve çoklu kitleleri tanımlamada önemlidir

Anahtar Kelimeler

Hepatosellüler Karsinom Alfa-Feto Protein Görüntüleme Retrospektif

Kaynakça

  • Dogan E, Yalcin S, Koca D, Olmez A. Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev 2012;13(6):2985-90.
  • Bosch FX, Ribes J. Epidemiology of primary liver cancer. Global epidemiology. In: Tabor E. editors. Vıruses and Liver Cancer. Netherlands: Elsevier Science B.V; 2002:1-16.
  • Sewart BW, Kleihues P. World Cancer Report. Lyon: IARC Pres 2003:11–9.
  • Uzunalimoglu O, Yurdaydin C, Cetinkaya H, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001;46:1022–8.
  • Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325(10):675-80.
  • Abdo AA, Karim HA, Al Fuhaid T, et al. Diagnosis and management of hepatocellular carcinoma. The Saudi Journal of Gastroenterology 2007;13 (suppl):S1-24.
  • Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14(27): 4300-8.
  • Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75(3):347-54.
  • Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50.
  • Cottone M, Turri M, Caltagirone M, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994;21(6):1029- 34.
  • Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313(20):1256-62.
  • Fargion S, Fracanzani AL, Piperno A, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994 20(6):1426-31.
  • Polio J, Enriquez RE, Chow A, Wood WM, Atterbury CE. Hepatocellular carcinoma in Wilson's disease. Case report and review of the literature. J Clin Gastroenterol 1989;11(2):220-4.
  • Kew M. Hepatic tumors and cysts. In: Feldman M, Frıedman SL, Brandt LJ editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Philadelphia: Saunders, 2006:2007-33.
  • Pons F, Llovet JM. Approaching focal liver lesions. Rev Esp Enferm Dig 2004;96(8):567-73.
  • Reddy KR, Schiff E. Approach to a liver mass. Seminars in liver disease 1993; 13(4): 423-35.
  • Rubin RA, Mithchell DG. Evaluation of the solid hepatic mass. Med Clin North Am 1996;80(5): 907-28.
  • Ros PR, Davis GL. The incidental focal liver lesion: photon, proton, or needle? Hepatology 1998;27(5): 1183-90.
  • Pons F, Llovet JM. Approaching focal liver lesions. Rev Esp Enferm Dig 2004;96(8):567-77.
  • Song do S, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol 2012;18(3):258-67.
  • Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007;33(5):437-47.
  • Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19(1):61-7.
  • Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994, 20(1):65-71.
  • Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78(5):977-83.
  • Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009;16(7):453-463.
  • Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett 2009;286(1):5-8.
  • Gomaa AI, Khan SA, Leen ELS, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009;15(11): 1301-14.
  • Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett 2009;286(1):5-8.
  • Leong TY, Leong AS. Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB 2005;7(1):5- 15.
  • But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008;14(11):1652-6.
Toplam 30 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Temel T Bu kişi benim

Yayımlanma Tarihi 1 Nisan 2015
Yayımlandığı Sayı Yıl 2015 Cilt: 7 Sayı: 1

Kaynak Göster

APA T, T. (2015). Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi. Konuralp Medical Journal, 7(1), 57-60. https://doi.org/10.18521/ktd.95339
AMA T T. Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi. Konuralp Medical Journal. Nisan 2015;7(1):57-60. doi:10.18521/ktd.95339
Chicago T, Temel. “Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi”. Konuralp Medical Journal 7, sy. 1 (Nisan 2015): 57-60. https://doi.org/10.18521/ktd.95339.
EndNote T T (01 Nisan 2015) Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi. Konuralp Medical Journal 7 1 57–60.
IEEE T. T, “Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi”, Konuralp Medical Journal, c. 7, sy. 1, ss. 57–60, 2015, doi: 10.18521/ktd.95339.
ISNAD T, Temel. “Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi”. Konuralp Medical Journal 7/1 (Nisan 2015), 57-60. https://doi.org/10.18521/ktd.95339.
JAMA T T. Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi. Konuralp Medical Journal. 2015;7:57–60.
MLA T, Temel. “Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi”. Konuralp Medical Journal, c. 7, sy. 1, 2015, ss. 57-60, doi:10.18521/ktd.95339.
Vancouver T T. Hepatosellüler Karsinomlu Hastaların Geriye-Dönük Değerlendirilmesi-Tek Merkez Deneyimi. Konuralp Medical Journal. 2015;7(1):57-60.